



## Medical Policy

# Biomarker Testing in Risk Assessment and Management of Cardiovascular Disease

### Table of Contents

- [Policy: Commercial](#)
- [Description](#)
- [Information Pertaining to All Policies](#)
- [Authorization Information](#)
- [Policy History](#)
- [Coding Information](#)
- [References](#)

### Policy Number: 283

BCBSA Reference Number: 2.04.65 (For Plan internal use only)

### Related Policies

None

### Policy

#### Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Measurement of nontraditional lipid and non-lipid biomarkers (ie, apolipoprotein B, apolipoprotein AI, apolipoprotein E, low-density lipoprotein subclass, high-density lipoprotein subclass, lipoprotein [a], B-type natriuretic peptide, cystatin C, fibrinogen, leptin) is considered **INVESTIGATIONAL** as an adjunct to low-density lipoprotein cholesterol in the risk assessment and management of cardiovascular disease.

Measurement of lipoprotein-associated phospholipase A<sub>2</sub> is considered **INVESTIGATIONAL**

Cardiovascular disease risk panels, consisting of multiple individual biomarkers intended to assess cardiac risk (other than simple lipid panels, see Policy Guidelines section), are considered **INVESTIGATIONAL**

#### Policy Guidelines

A simple lipid panel is generally composed of the following lipid measures:

- Total cholesterol
- Low-density lipoprotein cholesterol
- High-density lipoprotein cholesterol
- Triglycerides.

Certain calculated ratios (eg, total/high-density lipoprotein cholesterol) may also be reported as part of a simple lipid panel.

Other types of lipid testing (ie, apolipoproteins, lipid particle number or particle size, lipoprotein [a]) are not considered components of a simple lipid profile.

This policy does not address the use of panels of biomarkers in the diagnosis of acute myocardial infarction.

## Prior Authorization Information

### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

### Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This is <b>not</b> a covered service.
Commercial PPO and Indemnity	This is <b>not</b> a covered service.

## CPT Codes / HCPCS Codes / ICD Codes

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

*The following codes are included below for informational purposes only; this is not an all-inclusive list.*

**The following CPT codes are considered investigational for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:**

### CPT Codes

CPT codes:	Code Description
82610	Cystatin C
83695	Lipoprotein A
83698	Lipoprotein-associated phospholipase A2 (Lp-PLA2)
83700	Lipoprotein, blood; electrophoretic separation and quantitation
83701	Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (eg, electrophoresis, ultracentrifugation)
83704	Lipoprotein, blood; quantitation of lipoprotein particle number(s) (eg, by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed
83880	Natriuretic peptide
85384	Fibrinogen; activity
85385	Fibrinogen; antigen
0052U	Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation
0377U	Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables)
0541U	Cardiovascular disease (HDL reverse cholesterol transport), cholesterol efflux capacity, LC-MS/MS, quantitative measurement of 5 distinct HDL-bound apolipoproteins (apolipoproteins A1, C1, C2, C3, and C4), serum, algorithm reported as prediction of coronary artery disease (pCAD) score

## Description

## Cardiovascular Disease

Cardiovascular disease (CVD) remains the single largest cause of morbidity and mortality in the developed world. Mortality from CVD has accounted for 1 in 4 deaths in the United States, and there are numerous socio-economic factors that affect CVD mortality rates.<sup>1</sup> Lower-income, race, age, and behavioral factors all have a significant impact on health outcome disparities associated with CVD.

As a result, accurate prediction of CVD risk is a component of medical care that has the potential to focus on and direct preventive and diagnostic activities. Current methods of risk prediction in use in general clinical care are not highly accurate and, as a result, there is a potential unmet need for improved risk prediction instruments.

## Risk Assessment

Although treatment for elevated coronary disease risk with statins targets cholesterol levels, selection for treatment involves estimation of future CAD risk using well-validated prediction models that use additional variables.

Components of CVD risk include family history, cigarette smoking, hypertension, and lifestyle factors such as diet and exercise. Also, numerous laboratory tests have been associated with CVD risk, most prominently lipids such as low-density lipoprotein (LDL) and high-density lipoprotein (HDL). These clinical and lipid factors are often combined into simple risk prediction instruments, such as the Framingham Risk Score.<sup>2</sup> The Framingham Risk Score provides an estimate of the 10-year risk for developing cardiac disease and is currently used in clinical care to determine the aggressiveness of risk factor intervention, such as the decision to treat hyperlipidemia with statins.

Many additional biomarkers, genetic factors, and radiologic measures have been associated with an increased risk of CVD. Over 100 emerging risk factors have been proposed as useful for refining estimates of CVD risk.<sup>3,4,5</sup> Some general categories of these potential risk factors are as follows:

- **Lipid markers.** In addition to LDL and HDL, other lipid markers may have predictive ability, including the apolipoproteins, lipoprotein (a) (Lp[a]), lipid subfractions, and/or other measures.
- **Inflammatory markers.** Many measures of inflammation have been linked to the likelihood of CVD. High-sensitivity C-reactive protein (hs-CRP) is an example of an inflammatory marker; others include fibrinogen, interleukins, and tumor necrosis factor.
- **Metabolic syndrome biomarkers.** Measures associated with metabolic syndromes, such as specific dyslipidemic profiles or serum insulin levels, have been associated with an increased risk of CVD.
- **Genetic markers.** A number of variants associated with increased thrombosis risk, such as the 5,10-methylene tetrahydrofolate reductase (*MTHFR*) variant or the prothrombin gene variants, have been associated with increased CVD risk. Also, numerous single nucleotide variants have been associated with CVD in large genome-wide studies.

## Risk Panel Testing

Cardiovascular disease risk panels may contain measures from 1 or all of the previous categories and may include other measures not previously listed such as radiologic markers (carotid medial thickness, coronary artery calcium score). Some CVD risk panels are relatively limited, including a few markers in addition to standard lipids. Others include a wide variety of potential risk factors from a number of different categories, often including both genetic and nongenetic risk factors. Other panels are composed entirely of genetic markers.

Some examples of commercially available CVD risk panels are as follows:

- **CV Health Plus Genomics™ Panel (Genova Diagnostics):** apolipoprotein (apo) E; prothrombin; factor V Leiden; fibrinogen; HDL; HDL size; HDL particle number; homocysteine; LDL; LDL size; LDL particle number; Lp(a); lipoprotein-associated phospholipase A2 (Lp-PLA2); *MTHFR* gene; triglycerides; very-low-density lipoprotein (VLDL); VLDL size; vitamin D; hs-CRP.
- **CV Health Plus™ Panel (Genova Diagnostics):** fibrinogen; HDL; HDL size; HDL particle number; homocysteine; LDL; LDL size; LDL particle number; lipid panel; Lp(a); Lp-PLA2; triglycerides; VLDL; VLDL size; vitamin D; hs-CRP.

- **CVD Inflammatory Profile (Cleveland HeartLab):** hs-CRP, urinary microalbumin, myeloperoxidase, Lp-PLA2, F<sub>2</sub> isoprostanes.
- **Applied Genetics Cardiac Panel:** genetic variants associated with coronary artery disease: cytochrome p450 variants associated with the metabolism of clopidogrel, ticagrelor, warfarin, beta-blockers, rivaroxaban, prasugrel (2C19, 2C9/VKORC1, 2D6, 3A4/3A5), factor V Leiden, prothrombin gene, *MTHFR* gene, *APOE* gene.
- **Genetiks Genetic Diagnosis and Research Center Cardiovascular Risk Panel:** factor V Leiden, factor V R2, prothrombin gene, factor XIII, fibrinogen-455, plasminogen activator inhibitor-1, platelet glycoprotein (GP) IIIA variant human platelet antigen (HPA)-1 (PLA1/2), *MTHFR* gene, angiotensin-converting enzyme insertion/deletion, apo B, apo E.

In addition to panels that are specifically focused on CVD risk, a number of commercially available panels include markers associated with cardiovascular health, along with a range of other markers that have been associated with inflammation, thyroid disorders and other hormonal deficiencies, and other disorders. An example of these panels is:

- **Advanced Health Panel (Thorne):** total cholesterol, HDL, LDL, triglycerides, HDL ratios, non-HDL cholesterol, LDL particle number, small LDL, medium LDL, LDL pattern, LDL peak size, large HDL, apo A1, apo B, Lp(a), cortisol, hs-CRP, homocysteine, glucose, hemoglobin A1c, insulin, homeostatic model assessment for insulin resistance, free T4, free T3, thyroid-stimulating hormone, reverse T3, dehydroepiandrosterone sulfate, estradiol, follicle stimulating hormone, luteinizing hormone, sex hormone binding globulin, total testosterone, free testosterone, albumin, globulin, albumin/globulin ratio, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, total bilirubin, total serum protein, blood urea nitrogen, creatinine, blood urea nitrogen/creatinine ratio, estimated glomerular filtration rate from creatinine, estimated glomerular filtration rate from cystatin C, cystatin C, fibrinogen, platelet count, white cell count, absolute neutrophils, lymphocytes, absolute lymphocytes, monocytes, absolute monocytes, eosinophils, absolute eosinophils, basophils, absolute basophils, red blood cell count, hemoglobin, hematocrit, mean platelet volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean corpuscular volume, red cell distribution width, folate, vitamin B12, vitamin D, red blood cell magnesium, calcium, carbon dioxide, chloride, potassium, sodium, ferritin, iron total iron binding capacity, omega-3 index, omega-6 to omega-3 ratio, arachidonic acid, eicosapentaenoic acid, eicosapentaenoic acid/arachidonic acid ratio, docosahexaenoic acid, free fatty acids.<sup>6</sup>

### Low-density Lipoproteins and Cardiovascular Disease

Low-density lipoproteins (LDLs) have been identified as the major atherogenic lipoproteins and have long been identified by the National Cholesterol Education Project as the primary target of cholesterol-lowering therapy. An LDL particle consists of a surface coat composed of phospholipids, free cholesterol, and apolipoproteins surrounding an inner lipid core composed of cholesterol ester and triglycerides. Traditional lipid risk factors such as LDL cholesterol (LDL-C), while predictive on a population basis, are weaker markers of risk on an individual basis. Only a minority of subjects with elevated LDL and cholesterol levels will develop clinical disease, and up to 50% of cases of coronary artery disease (CAD) occur in subjects with "normal" levels of total cholesterol and LDL-C. Thus, there is considerable potential to improve the accuracy of current cardiovascular risk prediction models.

Other non-lipid markers have been identified as being associated with cardiovascular disease (CVD), including B-type natriuretic peptide, cystatin C, fibrinogen, and leptin. These biomarkers may have a predictive role in identifying CVD risk or in targeting therapy. In the United States, social, biological, and environmental disparities exist in the prevalence, morbidity, and mortality rates that are associated with CVD.<sup>7</sup> Population subgroups that are most significantly adversely affected by such disparities included Black and Hispanic Americans, individuals with low socioeconomic status, and individuals who live in rural settings.

### Lipid Markers

#### Apolipoprotein B

Apolipoprotein (Apo) B is the major protein moiety of all lipoproteins, except for high-density lipoprotein (HDL). The most abundant form of apo B, large B or B<sub>100</sub>, constitutes the apo B found in LDL and very-low

density LDL. Because LDL and very-low density LDL each contain 1 molecule of apo B, the measurement of apo B reflects the total number of these atherogenic particles, 90% of which are LDL. Because LDL particles can vary in size and in cholesterol content, for a given concentration of LDL-C, there can be a wide variety in size and numbers of LDL particles. Thus, it has been postulated that apo B is a better measure of the atherogenic potential of serum LDL than LDL concentration.

### **Apolipoprotein AI**

High-density lipoprotein contains 2 associated apolipoproteins (ie, apo AI, apo AII). High-density lipoprotein particles can also be classified by whether they contain apo AI only or they contain apo AI and apo AII. All lipoproteins contain apo AI, and some also contain apo AII. Because all HDL particles contain apo AI, this lipid marker can be used as an approximation for HDL number, similar to the way apo B has been proposed as an approximation of the LDL number.

Direct measurement of apo AI has been proposed as more accurate than the traditional use of HDL level in the evaluation of cardioprotective, or “good,” cholesterol. In addition, the ratio of apo B/apo AI has been proposed as a superior measure of the ratio of proatherogenic (ie, “bad”) cholesterol to anti-atherogenic (ie, “good”) cholesterol.

### **Apolipoprotein E**

Apolipoprotein E is the primary apolipoprotein found in very-low density LDLs and chylomicrons. Apolipoprotein E is the primary binding protein for LDL receptors in the liver and is thought to play an important role in lipid metabolism. The apolipoprotein E (*APOE*) gene is polymorphic, consisting of 3 epsilon alleles (e2, e3, e4) that code for 3 protein isoforms, known as E2, E3, and E4, which differ from one another by one amino acid. These molecules mediate lipid metabolism through their different interactions with LDL receptors. The genotype of apo E alleles can be assessed by gene amplification techniques, or the *APOE* phenotype can be assessed by measuring plasma levels of apo E.

It has been proposed that various *APOE* genotypes are more atherogenic than others and that *APOE* measurement may provide information on the risk of CAD beyond traditional risk factor measurement. It has also been proposed that the *APOE* genotype may be useful in the selection of specific components of lipid-lowering therapy, such as drug selection. In the major lipid-lowering intervention trials, including trials of statin therapy, there is considerable variability in response to therapy that cannot be explained by factors such as compliance. The *APOE* genotype may be a factor that determines an individual's degree of response to interventions such as statin therapy.

### **High-Density Lipoprotein Subclass**

High-density lipoprotein particles exhibit considerable heterogeneity, and it has been proposed that various subclasses of HDL may have a greater role in protection from atherosclerosis. Particles of HDL can be characterized based on size or density and/or on apolipoprotein composition. Using size or density, HDL can be classified into HDL<sub>2</sub>, the larger, less dense particles that may have the greatest degree of cardioprotection, and HDL<sub>3</sub>, which are smaller, denser particles.

An alternative to measuring the concentration of subclasses of HDL (eg, HDL<sub>2</sub>, HDL<sub>3</sub>) is a direct measurement of HDL particle size and/or number. Particle size can be measured by nuclear magnetic resonance spectroscopy or by gradient-gel electrophoresis. High-density lipoprotein particle numbers can be measured by nuclear magnetic resonance spectroscopy. Several commercial labs offer these measurements of HDL particle size and number. Measurement of apo AI has used HDL particle number as a surrogate, based on the premise that each HDL particle contains a single apo AI molecule.

### **Low-Density Lipoprotein Subclass**

Two main subclass patterns of LDL, called A and B, have been described. In subclass pattern A, particles have a diameter larger than 25 nm and are less dense, while in subclass pattern B, particles have a diameter less than 25 nm and a higher density. Subclass pattern B is a common inherited disorder associated with a more atherogenic lipoprotein profile, also termed “atherogenic dyslipidemia.” In addition to small, dense LDL, this pattern includes elevated levels of triglycerides, elevated levels of apo B, and low levels of HDL. This lipid profile is commonly seen in type 2 diabetes and is a component of the “metabolic

syndrome,” defined by the Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) to also include high normal blood pressure, insulin resistance, increased levels of inflammatory markers such as C-reactive protein, and a prothrombotic state. The presence of the metabolic syndrome is considered by Adult Treatment Panel III to be a substantial risk-enhancing factor for CAD.

Low-density lipoprotein size has also been proposed as a potentially useful measure of treatment response. Lipid-lowering treatment decreases total LDL and may also induce a shift in the type of LDL, from smaller, dense particles to larger particles. It has been proposed that this shift in lipid profile may be beneficial in reducing the risk for CAD independent of the total LDL level. Also, some drugs may cause a greater shift in lipid profiles than others. Niacin and/or fibrates may cause a greater shift from small to large LDL size than statins. Therefore, measurement of LDL size may potentially play a role in drug selection or may be useful in deciding whether to use a combination of drugs rather than a statin alone.

In addition to the size of LDL particles, interest has been shown in assessing the concentration of LDL particles as a distinct cardiac risk factor. For example, the commonly performed test for LDL-C is not a direct measure of LDL, but, chosen for its convenience, measures the amount of cholesterol incorporated into LDL particles. Because LDL particles carry much of the cholesterol in the bloodstream, the concentration of cholesterol in LDL correlates reasonably well with the number of LDL particles when examined in large populations. However, for an individual patient, the LDL level may not reflect the number of particles due to varying levels of cholesterol in different sized particles. It is proposed that the discrepancy between the number of LDL particles and the serum level of LDL represents a significant source of unrecognized atherogenic risk. The size and number of particles are interrelated. For example, all LDL particles can invade the arterial wall and initiate atherosclerosis. However, small, dense particles are thought to be more atherogenic than larger particles. Therefore, for patients with elevated numbers of LDL particles, the cardiac risk may be further enhanced when the particles are smaller versus larger.

### **Lipoprotein (a)**

Lipoprotein (Lp) (a) is a lipid-rich particle similar to LDL. The major apolipoprotein associated with LDL is Apo B; in Lp(a), however, there is an additional apo A covalently linked to apo B. The apo A molecule is structurally similar to plasminogen, suggesting that Lp(a) may contribute to the thrombotic and atherogenic basis of CVD. Levels of Lp(a) are relatively stable in individuals over time but vary up to 1000-fold between individuals, presumably on a genetic basis. The similarity between Lp(a) and fibrinogen has stimulated intense interest in Lp(a) as a link between atherosclerosis and thrombosis. In addition, approximately 20% of patients with CAD have elevated Lp(a) levels. Therefore, it has been proposed that levels of Lp(a) may be an independent risk factor for CAD.

### **Non-Lipid Markers**

#### **B-type or Brain Natriuretic Peptide**

Brain natriuretic peptide (BNP, also called B-type natriuretic peptide) is an amino acid polypeptide secreted primarily by the ventricles of the heart when the pressure to the cardiac muscles increases or there is myocardial ischemia. Elevations in BNP levels reflect deterioration in cardiac loading levels and may predict adverse events. Brain natriuretic peptide has been studied as a biomarker for managing heart failure and predicting cardiovascular and heart failure risk.

#### **Cystatin C**

Cystatin C is a small serine protease inhibitor protein secreted from all functional cells in the body. It has primarily been used as a biomarker of kidney function. Cystatin C has also been studied to determine whether it may serve as a biomarker for predicting cardiovascular risk. Cystatin C is encoded by the *CST3* gene.

#### **Fibrinogen**

Fibrinogen is a circulating clotting factor and precursor of fibrin. It is important in platelet aggregation and a determinant of blood viscosity. Fibrinogen levels have been shown to be associated with future risk of CVD and all-cause mortality.

## Leptin

Leptin is a protein secreted by fat cells that have been found to be elevated in heart disease. Leptin has been studied to determine if it has any relation to the development of CVD.

## Lipoprotein-associated Phospholipase A<sub>2</sub>

Lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>), also known as platelet-activating factor acetylhydrolase, is an enzyme that hydrolyzes phospholipids and is primarily associated with LDLs.

Accumulating evidence has suggested that Lp-PLA<sub>2</sub> is a biomarker of CAD and may have a proinflammatory role in the progression of atherosclerosis. Recognition that atherosclerosis represents, in part, an inflammatory process has created considerable interest in the measurement of pro-inflammatory factors as part of cardiovascular disease risk assessment.

Interest in Lp-PLA<sub>2</sub> as a possible causal risk factor for CAD has generated the development and testing of Lp-PLA<sub>2</sub> inhibitors as a new class of drugs to reduce the risk of CAD. However, clinical trials of Lp-PLA<sub>2</sub> inhibitors have not shown significant reductions in CAD endpoints.<sup>8,9,10</sup> Furthermore, assessment of Lp-PLA<sub>2</sub> levels has not been used in the selection or management of subjects in the clinical trials.

## Summary

### Description

Numerous lipid and non-lipid biomarkers have been proposed as potential risk markers for cardiovascular disease. Biomarkers assessed herein include apolipoprotein B, apolipoprotein AI, apolipoprotein E, B-type natriuretic peptide, cystatin C, fibrinogen, high-density lipoprotein subclass, leptin, low-density lipoprotein subclass, lipoprotein(a), and lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>). These biomarkers have been studied as alternatives or additions to standard lipid panels for risk stratification in cardiovascular disease or as treatment targets for lipid-lowering therapy. Cardiovascular risk panels refer to different combinations of cardiac markers that are intended to evaluate the risk of cardiovascular disease. There are numerous commercially available risk panels that include different combinations of lipids, noncardiac biomarkers, measures of inflammation, metabolic parameters, and/or genetic markers. Risk panels report the results of multiple individual tests, as distinguished from quantitative risk scores that combine the results of multiple markers into a single score.

### Summary of Evidence

For individuals who are asymptomatic with risk of cardiovascular disease (CVD) who receive nontraditional cardiac biomarker testing (eg, apolipoprotein B [apo B], apolipoprotein AI [apo AI], apolipoprotein E [apo E], high-density lipoprotein [HDL] subclass, low-density lipoprotein [LDL] subclass, Lp[a], B-type natriuretic peptide [BNP], cystatin C, fibrinogen, leptin), the evidence includes systematic reviews, meta-analyses, and large, prospective cohort studies. Relevant outcomes are overall survival (OS), other test performance measures, change in disease status, morbid events, and medication use. The evidence from cohort studies and meta-analyses of these studies has suggested that some of these markers are associated with increased cardiovascular risk and may provide incremental accuracy in risk prediction. In particular, apo B and apo AI have been identified as adding some incremental predictive value. However, it has not been established whether the incremental accuracy provides clinically important information beyond that of traditional lipid measures. Furthermore, no study has provided high-quality evidence that measurement of markers leads to changes in management that improve health outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with hyperlipidemia managed with lipid-lowering therapy who receive nontraditional cardiac biomarker testing (eg, apo B, apo AI, apo E, HDL subclass, LDL subclass, Lp[a], BNP, cystatin C, fibrinogen, leptin), the evidence includes analyses of the intervention arm(s) of lipid-lowering medication trials. Relevant outcomes are OS, change in disease status, morbid events, and medication use. In particular, apo B, apo AI, and apo E have been evaluated as markers of lipid-lowering treatment success, and evidence from the intervention arms of several randomized controlled trials (RCTs) has suggested that these markers are associated with treatment success. However, there is no direct evidence that using markers other than LDL and HDL as a lipid-lowering treatment target leads to improved health outcomes.

The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have a risk of CVD who receive Lp-PLA<sub>2</sub> testing, the evidence includes studies of the association between Lp-PLA<sub>2</sub> and various CAD outcomes. Relevant outcomes are overall survival, disease-specific survival, and test validity. The studies have demonstrated that Lp-PLA<sub>2</sub> levels are an independent predictor of CVD. Although Lp-PLA<sub>2</sub> levels are associated with CVD risk, changes in patient management that would occur as a result of obtaining Lp-PLA<sub>2</sub> levels in practice are not well-defined. To demonstrate clinical utility, clinicians must have the tools to incorporate Lp-PLA<sub>2</sub> test results into existing risk prediction models that improve classification into risk categories, alter treatment decisions, and lead to improved health outcomes. Direct evidence for such improved health outcomes with Lp-PLA<sub>2</sub> testing in clinical practice is lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

For individuals who have risk factors for cardiovascular disease (CVD) who receive CVD risk panels, the evidence includes multiple cohorts and case-control studies and systematic reviews of these studies. Relevant outcomes are test validity, other test performance measures, change in disease status, and morbid events. The available evidence from cohort and case-control studies indicates that many of the individual risk factors included in CVD risk panels are associated with an increased risk of CVD. However, it is not clear how the results of individual risk factors impact management changes, so it is also uncertain how the panels will impact management decisions. Given the lack of evidence for the clinical utility of any individual risk factor beyond simple lipid measures, it is unlikely that the use of CVD risk panels improves outcomes. Studies that have evaluated the clinical validity of panels of multiple markers have not assessed management changes that would occur as a result of testing or demonstrated improvements in outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## Policy History

Date	Action
4/2025	Clarified coding information.
2/2025	Annual policy review. References updated. Policy statements unchanged.
4/2024	Annual policy review. Policy clarified. Policy statements from MP 558 Measurement of Lipoprotein-Associated Phospholipase A2 in the Assessment of Cardiovascular Risk and MP 664 Cardiovascular Risk Panels were combined into MP 283. Evidence reviews not updated at this time. Use of "novel" edited to "nontraditional" in policy statements; intent unchanged.
1/2024	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
4/2023	Clarified coding information.
2/2023	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
2/2022	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
2/2021	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2021	Medicare information removed. See MP #132 Medicare Advantage Management for local coverage determination and national coverage determination reference.
1/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
2/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
7/2018	Clarified coding information.
3/2018	Annual policy review. Description, summary, and references updated. Policy statements unchanged.



1/2017	Annual policy review. New references added.
1/2017	Clarified coding information for the 2017 code changes.
6/2016	Clarified coding information.
11/2015	Annual policy review. New references added.
7/2015	Clarified coding information.
3/2014	Annual policy review. Not medically necessary and investigational indications described; title changed. Effective 3/1/2014. Coverage for B-type natriuretic peptide testing for Medicare Advantage clarified. Code information clarified.
3/2013	Updated to add non-covered code 83701.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
5/2/2011	Revised date.
4/2011	Medical Policy Group- Cardiology and Pulmonology. No changes to policy statements.
11/1/2010	Medical Policy #283 effective describing on-going non-coverage.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. Niakouei A, Tehrani M, Fulton L. Health Disparities and Cardiovascular Disease. Healthcare (Basel). Mar 22 2020; 8(1). PMID 32235705
2. D'Agostino RB, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. Jul 11 2001; 286(2): 180-7. PMID 11448281
3. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. Oct 06 2009; 151(7): 496-507. PMID 19805772
4. Brotman DJ, Walker E, Lauer MS, et al. In search of fewer independent risk factors. Arch Intern Med. Jan 24 2005; 165(2): 138-45. PMID 15668358
5. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. Dec 14 2010; 56(25): e50-103. PMID 21144964
6. Thorne. Advanced Health Panel. <https://www.thorne.com/products/dp/advanced-health-panel>. Accessed October 30, 2024.
7. Mensah GA, Mokdad AH, Ford ES, et al. State of disparities in cardiovascular health in the United States. Circulation. Mar 15 2005; 111(10): 1233-41. PMID 15769763
8. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. May 01 2014; 370(18): 1702-11. PMID 24678955
9. O'Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. Sep 10 2014; 312(10): 1006-15. PMID 25173516
10. Nicholls SJ, Kastelein JJ, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. Jan 15 2014; 311(3): 252-62. PMID 24247616
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel

- on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*. May 16 2001; 285(19): 2486-97. PMID 11368702
12. Perera R, McFadden E, McLellan J, et al. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. *Health Technol Assess*. Dec 2015; 19(100): 1-401, vii-viii. PMID 26680162
  13. Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. *J Am Heart Assoc*. Apr 14 2014; 3(2): e000759. PMID 24732920
  14. van Holten TC, Waanders LF, de Groot PG, et al. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. *PLoS One*. 2013; 8(4): e62080. PMID 23630624
  15. Tzoulaki I, Siontis KC, Evangelou E, et al. Bias in associations of emerging biomarkers with cardiovascular disease. *JAMA Intern Med*. Apr 22 2013; 173(8): 664-71. PMID 23529078
  16. Willis A, Davies M, Yates T, et al. Primary prevention of cardiovascular disease using validated risk scores: a systematic review. *J R Soc Med*. Aug 2012; 105(8): 348-56. PMID 22907552
  17. Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. *Am J Cardiol*. Nov 15 2012; 110(10): 1468-76. PMID 22906895
  18. Di Angelantonio E, Gao P, Pennells L, et al. Lipid-related markers and cardiovascular disease prediction. *JAMA*. Jun 20 2012; 307(23): 2499-506. PMID 22797450
  19. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. *Circulation*. Aug 01 1996; 94(3): 273-8. PMID 8759066
  20. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. *Lancet*. Dec 15 2001; 358(9298): 2026-33. PMID 11755609
  21. Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. *JAMA*. Jul 20 2005; 294(3): 326-33. PMID 16030277
  22. Benn M, Nordestgaard BG, Jensen GB, et al. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. *Arterioscler Thromb Vasc Biol*. Mar 2007; 27(3): 661-70. PMID 17170368
  23. Kappelle PJ, Gansevoort RT, Hillege JL, et al. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. *J Intern Med*. Feb 2011; 269(2): 232-42. PMID 21129046
  24. Pencina MJ, D'Agostino RB, Zdrojewski T, et al. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. *Eur J Prev Cardiol*. Oct 2015; 22(10): 1321-7. PMID 25633587
  25. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*. Sep 04 2001; 104(10): 1108-13. PMID 11535564
  26. Rasouli M, Kiasari AM, Mokhberi V. The ratio of apoB/apoA-I, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. *Clin Chem Lab Med*. 2006; 44(8): 1015-21. PMID 16879071
  27. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. *J Intern Med*. Feb 2004; 255(2): 188-205. PMID 14746556
  28. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA*. Feb 14 2007; 297(6): 611-9. PMID 17299196
  29. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. *JAMA*. Aug 15 2007; 298(7): 776-85. PMID 17699011

30. Sniderman AD, Islam S, Yusuf S, et al. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. *Atherosclerosis*. Dec 2012; 225(2): 444-9. PMID 23068583
31. Clarke R, Emberson JR, Parish S, et al. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. *Arch Intern Med*. Jul 09 2007; 167(13): 1373-8. PMID 17620530
32. van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. *Ann Intern Med*. May 01 2007; 146(9): 640-8. PMID 17470832
33. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). *Circulation*. Feb 08 2000; 101(5): 477-84. PMID 10662743
34. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. *Circulation*. Mar 12 2002; 105(10): 1162-9. PMID 11889008
35. Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. *Circulation*. Jun 10 2008; 117(23): 3002-9. PMID 18519851
36. Mora S, Wenger NK, Demicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. *Circulation*. Apr 24 2012; 125(16): 1979-87. PMID 22461416
37. Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. *JAMA*. Sep 19 2007; 298(11): 1300-11. PMID 17878422
38. Sofat R, Cooper JA, Kumari M, et al. Circulating Apolipoprotein E Concentration and Cardiovascular Disease Risk: Meta-analysis of Results from Three Studies. *PLoS Med*. Oct 2016; 13(10): e1002146. PMID 27755538
39. Koch W, Hoppmann P, Schömig A, et al. Apolipoprotein E gene epsilon2/epsilon3/epsilon4 polymorphism and myocardial infarction: case-control study in a large population sample. *Int J Cardiol*. Mar 28 2008; 125(1): 116-7. PMID 17433475
40. Kulminski AM, Ukraintseva SV, Arbeev KG, et al. Health-protective and adverse effects of the apolipoprotein E epsilon2 allele in older men. *J Am Geriatr Soc*. Mar 2008; 56(3): 478-83. PMID 18179501
41. Schmitz F, Mevissen V, Krantz C, et al. Robust association of the APOE epsilon4 allele with premature myocardial infarction especially in patients without hypercholesterolaemia: the Aachen study. *Eur J Clin Invest*. Feb 2007; 37(2): 106-8. PMID 17217375
42. Vaisi-Raygani A, Rahimi Z, Nomani H, et al. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. *Clin Biochem*. Oct 2007; 40(15): 1150-6. PMID 17689519
43. Ciftidoğan DY, Coskun S, Ulman C, et al. The association of apolipoprotein E polymorphism and lipid levels in children with a family history of premature coronary artery disease. *J Clin Lipidol*. 2012; 6(1): 81-7. PMID 22264578
44. Vasunilashorn S, Gleit DA, Lan CY, et al. Apolipoprotein E is associated with blood lipids and inflammation in Taiwanese older adults. *Atherosclerosis*. Nov 2011; 219(1): 349-54. PMID 21840004
45. de Andrade M, Thandi I, Brown S, et al. Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis. *Am J Hum Genet*. Jun 1995; 56(6): 1379-90. PMID 7762561
46. Eichner JE, Kuller LH, Orchard TJ, et al. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. *Am J Cardiol*. Jan 15 1993; 71(2): 160-5. PMID 8421977
47. Wilson PW, Myers RH, Larson MG, et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. *JAMA*. Dec 07 1994; 272(21): 1666-71. PMID 7966894
48. Wilson PW, Schaefer EJ, Larson MG, et al. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. *Arterioscler Thromb Vasc Biol*. Oct 1996; 16(10): 1250-5. PMID 8857921
49. Volcik KA, Barkley RA, Hutchinson RG, et al. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. *Am J Epidemiol*. Aug 15 2006; 164(4): 342-8. PMID 16760224

50. Singh K, Chandra A, Sperry T, et al. Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity: A Pooled Cohort Analysis. *Circulation*. Aug 18 2020; 142(7): 657-669. PMID 32804568
51. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. *Circulation*. Sep 10 2013; 128(11): 1189-97. PMID 24002795
52. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. *JAMA*. Sep 18 1996; 276(11): 882-8. PMID 8782637
53. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. *Circulation*. Jan 07 1997; 95(1): 69-75. PMID 8994419
54. Tzou WS, Douglas PS, Srinivasan SR, et al. Advanced lipoprotein testing does not improve identification of subclinical atherosclerosis in young adults: the Bogalusa Heart Study. *Ann Intern Med*. May 03 2005; 142(9): 742-50. PMID 15867406
55. Blake GJ, Otvos JD, Rifai N, et al. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. *Circulation*. Oct 08 2002; 106(15): 1930-7. PMID 12370215
56. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. *Arterioscler Thromb Vasc Biol*. Jul 01 2002; 22(7): 1175-80. PMID 12117734
57. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. *Am J Cardiol*. Jul 15 2002; 90(2): 89-94. PMID 12106834
58. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. *Am J Cardiol*. Oct 17 2002; 90(8A): 22i-29i. PMID 12419478
59. Rosenson RS, Underberg JA. Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. *Cardiovasc Drugs Ther*. Oct 2013; 27(5): 465-79. PMID 23893306
60. Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. *Circulation*. Feb 24 2009; 119(7): 931-9. PMID 19204302
61. Toth PP, Grabner M, Punekar RS, et al. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. *Atherosclerosis*. Aug 2014; 235(2): 585-91. PMID 24956532
62. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. *Arch Intern Med*. Mar 24 2008; 168(6): 598-608. PMID 18362252
63. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. *Stroke*. Jun 2007; 38(6): 1959-66. PMID 17478739
64. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *Circulation*. Feb 11 2014; 129(6): 635-42. PMID 24243886
65. Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). *J Am Coll Cardiol*. Oct 22 2013; 62(17): 1575-9. PMID 23973688
66. Kamstrup PR, Benn M, Tybjaerg-Hansen A, et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. *Circulation*. Jan 15 2008; 117(2): 176-84. PMID 18086931
67. Tzoulaki I, Murray GD, Lee AJ, et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. *Circulation*. Apr 24 2007; 115(16): 2119-27. PMID 17404162

68. Zakai NA, Katz R, Jenny NS, et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. *J Thromb Haemost.* Jun 2007; 5(6): 1128-35. PMID 17388967
69. Waldeyer C, Makarova N, Zeller T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. *Eur Heart J.* Aug 21 2017; 38(32): 2490-2498. PMID 28449027
70. Lee SR, Prasad A, Choi YS, et al. LPA Gene, Ethnicity, and Cardiovascular Events. *Circulation.* Jan 17 2017; 135(3): 251-263. PMID 27831500
71. Rigal M, Ruidavets JB, Viguier A, et al. Lipoprotein (a) and risk of ischemic stroke in young adults. *J Neurol Sci.* Jan 15 2007; 252(1): 39-44. PMID 17113602
72. Suk Danik J, Rifai N, Buring JE, et al. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. *J Am Coll Cardiol.* Jul 08 2008; 52(2): 124-31. PMID 18598891
73. Genser B, Dias KC, Siekmeier R, et al. Lipoprotein (a) and risk of cardiovascular disease--a systematic review and meta analysis of prospective studies. *Clin Lab.* 2011; 57(3-4): 143-56. PMID 21500721
74. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA.* Jul 22 2009; 302(4): 412-23. PMID 19622820
75. Vazirian F, Sadeghi M, Kelesidis T, et al. Predictive value of lipoprotein(a) in coronary artery calcification among asymptomatic cardiovascular disease subjects: A systematic review and meta-analysis. *Nutr Metab Cardiovasc Dis.* Nov 2023; 33(11): 2055-2066. PMID 37567791
76. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. *JAMA.* Apr 06 1994; 271(13): 999-1003. PMID 8139085
77. Nestel PJ, Barnes EH, Tonkin AM, et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. *Arterioscler Thromb Vasc Biol.* Dec 2013; 33(12): 2902-8. PMID 24092750
78. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. *JAMA.* Aug 21 1996; 276(7): 544-8. PMID 8709403
79. Ohira T, Schreiner PJ, Morrisett JD, et al. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. *Stroke.* Jun 2006; 37(6): 1407-12. PMID 16675734
80. Fogacci F, Cicero AF, D'Addato S, et al. Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study. *Eur J Intern Med.* Jan 2017; 37: 49-55. PMID 27553697
81. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. *JAMA.* Nov 10 1993; 270(18): 2195-9. PMID 8411602
82. Bolibar I, von Eckardstein A, Assmann G, et al. Short-term prognostic value of lipid measurements in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. *Thromb Haemost.* Dec 2000; 84(6): 955-60. PMID 11154140
83. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med.* Dec 24 2009; 361(26): 2518-28. PMID 20032323
84. Shaw LJ, Polk DM, Kahute TA, et al. Prognostic accuracy of B-natriuretic peptide measurements and coronary artery calcium in asymptomatic subjects (from the Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research [EISNER] study). *Am J Cardiol.* Nov 01 2009; 104(9): 1245-50. PMID 19840570
85. Wu Z, Pilbrow AP, Liew OW, et al. Circulating cardiac biomarkers improve risk stratification for incident cardiovascular disease in community dwelling populations. *EBioMedicine.* Aug 2022; 82: 104170. PMID 35850010
86. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. *JAMA.* Jul 01 2009; 302(1): 49-57. PMID 19567439
87. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med.* Feb 12 2004; 350(7): 655-63. PMID 14960742
88. Ito H, Pacold IV, Durazo-Arvizu R, et al. The effect of including cystatin C or creatinine in a cardiovascular risk model for asymptomatic individuals: the multi-ethnic study of atherosclerosis. *Am J Epidemiol.* Oct 15 2011; 174(8): 949-57. PMID 21880578

89. Lee M, Saver JL, Huang WH, et al. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. *Circ Cardiovasc Qual Outcomes*. Nov 2010; 3(6): 675-83. PMID 20923994
90. Luo J, Wang LP, Hu HF, et al. Cystatin C and cardiovascular or all-cause mortality risk in the general population: A meta-analysis. *Clin Chim Acta*. Oct 23 2015; 450: 39-45. PMID 26192218
91. Kengne AP, Czernichow S, Stamatakis E, et al. Fibrinogen and future cardiovascular disease in people with diabetes: aetiological associations and risk prediction using individual participant data from nine community-based prospective cohort studies. *Diab Vasc Dis Res*. Mar 2013; 10(2): 143-51. PMID 22786872
92. Willeit P, Thompson SG, Agewall S, et al. Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. *Eur J Prev Cardiol*. Jan 2016; 23(2): 194-205. PMID 25416041
93. Ahmadi-Abhari S, Luben RN, Wareham NJ, et al. Seventeen year risk of all-cause and cause-specific mortality associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study. *Eur J Epidemiol*. Jul 2013; 28(7): 541-50. PMID 23821244
94. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. *JAMA*. Oct 12 2005; 294(14): 1799-809. PMID 16219884
95. Kaptoge S, White IR, Thompson SG, et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. *Am J Epidemiol*. Oct 15 2007; 166(8): 867-79. PMID 17785713
96. Sattar N, Wannamethee G, Sarwar N, et al. Leptin and coronary heart disease: prospective study and systematic review. *J Am Coll Cardiol*. Jan 13 2009; 53(2): 167-75. PMID 19130985
97. Zeng R, Xu CH, Xu YN, et al. Association of leptin levels with pathogenetic risk of coronary heart disease and stroke: a meta-analysis. *Arq Bras Endocrinol Metabol*. Nov 2014; 58(8): 817-23. PMID 25465603
98. Yang H, Guo W, Li J, et al. Leptin concentration and risk of coronary heart disease and stroke: A systematic review and meta-analysis. *PLoS One*. 2017; 12(3): e0166360. PMID 28278178
99. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. *JAMA*. Mar 28 2012; 307(12): 1302-9. PMID 22453571
100. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *J Am Coll Cardiol*. Aug 05 2014; 64(5): 485-94. PMID 25082583
101. Ballantyne CM, Pitt B, Loscalzo J, et al. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting Undertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). *Am J Cardiol*. Feb 15 2013; 111(4): 506-9. PMID 23237107
102. Mora S, Glynn RJ, Boekholdt SM, et al. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). *J Am Coll Cardiol*. Apr 24 2012; 59(17): 1521-8. PMID 22516441
103. Ray KK, Cannon CP, Cairns R, et al. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. *Arterioscler Thromb Vasc Biol*. Mar 2009; 29(3): 424-30. PMID 19122170
104. Osei-Hwedie DO, Amar M, Sviridov D, et al. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. *Pharmacol Ther*. Apr 2011; 130(1): 83-91. PMID 21172387
105. Ordovas JM, Mooser V. The APOE locus and the pharmacogenetics of lipid response. *Curr Opin Lipidol*. Apr 2002; 13(2): 113-7. PMID 11891412
106. Sarkkinen E, Korhonen M, Erkkilä A, et al. Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol. *Am J Clin Nutr*. Dec 1998; 68(6): 1215-22. PMID 9846849

107. Carmena R, Roederer G, Mailloux H, et al. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. *Metabolism*. Jul 1993; 42(7): 895-901. PMID 8345800
108. Chiodini BD, Franzosi MG, Barlera S, et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. *Eur Heart J*. Aug 2007; 28(16): 1977-83. PMID 17567623
109. Donnelly LA, Palmer CN, Whitley AL, et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. *Pharmacogenet Genomics*. Apr 2008; 18(4): 279-87. PMID 18334912
110. Vossen CY, Hoffmann MM, Hahmann H, et al. Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program. *Clin Pharmacol Ther*. Aug 2008; 84(2): 222-7. PMID 18388879
111. Kwiterovich PO. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. *Am J Cardiol*. Oct 17 2002; 90(8A): 30i-47i. PMID 12419479
112. Superko HR, Berneis KK, Williams PT, et al. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. *Am J Cardiol*. Nov 01 2005; 96(9): 1266-72. PMID 16253595
113. Sirtori CR, Calabresi L, Pisciotta L, et al. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. *Nutr Metab Cardiovasc Dis*. Feb 2005; 15(1): 47-55. PMID 15871851
114. Arca M, Montali A, Pigna G, et al. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia. *Metabolism*. Nov 2007; 56(11): 1534-41. PMID 17950105
115. Rosenson RS, Wolff DA, Huskin AL, et al. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. *Diabetes Care*. Aug 2007; 30(8): 1945-51. PMID 17483155
116. Tokuno A, Hirano T, Hayashi T, et al. The effects of statin and fibrate on lowering small dense LDL-cholesterol in hyperlipidemic patients with type 2 diabetes. *J Atheroscler Thromb*. Jun 2007; 14(3): 128-32. PMID 17587764
117. Miller BD, Alderman EL, Haskell WL, et al. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. *Circulation*. Nov 01 1996; 94(9): 2146-53. PMID 8901665
118. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. *N Engl J Med*. Nov 08 1990; 323(19): 1289-98. PMID 2215615
119. Campos H, Moye LA, Glasser SP, et al. Low-density lipoprotein size, pravastatin treatment, and coronary events. *JAMA*. Sep 26 2001; 286(12): 1468-74. PMID 11572739
120. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADVICOR Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). *Am J Cardiol*. Mar 15 2003; 91(6): 667-72. PMID 12633795
121. van Wissen S, Smilde TJ, Trip MD, et al. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. *Heart*. Aug 2003; 89(8): 893-6. PMID 12860867
122. National Institutes of Health, National Heart Lung and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (NIH Publication No. 01-3670). 2001; <http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3xsum.pdf>. Accessed November 1, 2024.
123. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. *Lancet*. May 01 2010; 375(9725): 1536-44. PMID 20435228
124. Garza CA, Montori VM, McConnell JP, et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. *Mayo Clin Proc*. Feb 2007; 82(2): 159-65. PMID 17290721

125. Antonopoulos AS, Angelopoulos A, Papanikolaou P, et al. Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication: A Meta-Analysis. *JACC Cardiovasc Imaging*. Mar 2022; 15(3): 460-471. PMID 34801448
126. Gottlieb SS, Harris K, Todd J, et al. Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. *Clin Biochem*. Mar 2015; 48(4-5): 292-6. PMID 25541019
127. Patterson CC, Blankenberg S, Ben-Shlomo Y, et al. Which biomarkers are predictive specifically for cardiovascular or for non-cardiovascular mortality in men? Evidence from the Caerphilly Prospective Study (CaPS). *Int J Cardiol*. Dec 15 2015; 201: 113-8. PMID 26298350
128. Malachias MVB, Jhund PS, Claggett BL, et al. NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus. *J Am Heart Assoc*. Oct 20 2020; 9(19): e017462. PMID 32964800
129. Schoe A, Schippers EF, Ebmeyer S, et al. Predicting mortality and morbidity after elective cardiac surgery using vasoactive and inflammatory biomarkers with and without the EuroSCORE model. *Chest*. Nov 2014; 146(5): 1310-1318. PMID 24992322
130. Şaylık F, Akbulut T. Temporal relationship between serum calcium and triglyceride-glucose index and its impact on the incident of the acute coronary syndrome: a cross-lagged panel study. *Acta Cardiol*. Jul 2023; 78(5): 586-593. PMID 35969239
131. Mohebi R, van Kimmenade R, McCarthy CP, et al. Performance of a multi-biomarker panel for prediction of cardiovascular event in patients with chronic kidney disease. *Int J Cardiol*. Jan 15 2023; 371: 402-405. PMID 36202172
132. Safo SE, Haine L, Baker J, et al. Derivation of a Protein Risk Score for Cardiovascular Disease Among a Multiracial and Multiethnic HIV+ Cohort. *J Am Heart Assoc*. Jul 04 2023; 12(13): e027273. PMID 37345752
133. Wallentin L, Eriksson N, Olszowka M, et al. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. *PLoS Med*. Jan 2021; 18(1): e1003513. PMID 33439866
134. Wuopio J, Hilden J, Bring C, et al. Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study. *Atherosclerosis*. Nov 2018; 278: 97-102. PMID 30261474
135. Winkel P, Jakobsen JC, Hilden J, et al. Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial. *BMJ Open*. Aug 20 2020; 10(8): e033720. PMID 32819979
136. Welsh P, Kou L, Yu C, et al. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. *Eur J Heart Fail*. Feb 2018; 20(2): 268-277. PMID 28960777
137. Harari G, Green MS, Magid A, et al. Usefulness of Non-High-Density Lipoprotein Cholesterol as a Predictor of Cardiovascular Disease Mortality in Men in 22-Year Follow-Up. *Am J Cardiol*. Apr 15 2017; 119(8): 1193-1198. PMID 28267961
138. Kunutsor SK, Bakker SJ, James RW, et al. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. *Atherosclerosis*. Feb 2016; 245: 143-54. PMID 26724525
139. Keller T, Boeckel JN, Groß S, et al. Improved risk stratification in prevention by use of a panel of selected circulating microRNAs. *Sci Rep*. Jul 03 2017; 7(1): 4511. PMID 28674420
140. de Lemos JA, Ayers CR, Levine BD, et al. Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. *Circulation*. May 30 2017; 135(22): 2119-2132. PMID 28360032
141. Greisenegger S, Segal HC, Burgess AI, et al. Biomarkers and mortality after transient ischemic attack and minor ischemic stroke: population-based study. *Stroke*. Mar 2015; 46(3): 659-66. PMID 25649803
142. Cho S, Lee SH, Park S, et al. The additive value of multiple biomarkers in prediction of premature coronary artery disease. *Acta Cardiol*. Apr 2015; 70(2): 205-10. PMID 26148381
143. Wilsaard T, Mathiesen EB, Patwardhan A, et al. Clinically significant novel biomarkers for prediction of first ever myocardial infarction: the Tromsø Study. *Circ Cardiovasc Genet*. Apr 2015; 8(2): 363-71. PMID 25613532



144. Guarrera S, Fiorito G, Onland-Moret NC, et al. Gene-specific DNA methylation profiles and LINE-1 hypomethylation are associated with myocardial infarction risk. *Clin Epigenetics*. 2015; 7: 133. PMID 26705428
145. Lara J, Cooper R, Nissan J, et al. A proposed panel of biomarkers of healthy ageing. *BMC Med*. Sep 15 2015; 13: 222. PMID 26373927
146. Paynter NP, Chasman DI, Paré G, et al. Association between a literature-based genetic risk score and cardiovascular events in women. *JAMA*. Feb 17 2010; 303(7): 631-7. PMID 20159871
147. Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. *N Engl J Med*. May 15 2008; 358(20): 2107-16. PMID 18480203
148. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. Jul 13 2004; 110(2): 227-39. PMID 15249516
149. National Heart Lung and Blood Institute. Managing Blood Cholesterol in Adults: Systematic Evidence Review From the Cholesterol Expert Panel, 2013. Bethesda, MD: National Heart, Lung, and Blood Institute; 2013. <https://www.nhlbi.nih.gov/sites/default/files/media/docs/cholesterol-in-adults.pdf>. Accessed November 3, 2024.
150. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Jul 01 2014; 63(25 Pt B): 2889-934. PMID 24239923
151. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. Jun 24 2014; 129(25 Suppl 2): S49-73. PMID 24222018
152. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. Sep 10 2019; 140(11): e596-e646. PMID 30879355
153. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. *Diabetes Care*. Apr 2008; 31(4): 811-22. PMID 18375431
154. ElSayed NA, Aleppo G, Bannuru RR, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. *Diabetes Care*. Jan 01 2024; 47(Suppl 1): S179-S218. PMID 38078592
155. Jellinger PS, Handelsman Y, Rosenblit PD, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. *Endocr Pract*. Apr 2017; 23(Suppl 2): 1-87. PMID 28437620
156. Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. *Endocr Pract*. Oct 2020; 26(10): 1196-1224. PMID 33471721
157. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. *Endocr Pract*. Oct 2022; 28(10): 923-1049. PMID 35963508
158. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. Jan 01 2020; 41(1): 111-188. PMID 31504418
159. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. Sep 07 2021; 42(34): 3227-3337. PMID 34458905
160. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. *J Clin Lipidol*. 2014; 8(5): 473-88. PMID 25234560
161. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart

- Association Task Force on Clinical Practice Guidelines. *Circulation*. Jun 18 2019; 139(25): e1082-e1143. PMID 30586774
162. Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. *J Clin Lipidol*. 2019; 13(3): 374-392. PMID 31147269
163. Wilson PW, Jacobson TA, Martin SS, et al. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. *J Clin Lipidol*. Published online: September 24, 2021
164. National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification [CG181]. December 2023; <https://www.nice.org.uk/guidance/ng238>. Accessed November 5, 2024.
165. Curry SJ, Krist AH, Owens DK, et al. Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement. *JAMA*. Jul 17 2018; 320(3): 272-280. PMID 29998297